Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 54 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active, not recruitingNCT05973773Phase 3
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid TumorsActive, not recruitingNCT05971862Phase 1
• Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaActive, not recruitingNCT05971251Phase 1
• Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic DermatitisCompletedNCT05969730Not applicable
• Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusActive, not recruitingNCT05966480Phase 2
• A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT05963074Phase 2
• TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05955391Phase 2
• POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUTerminatedNCT05953688Phase 2
• A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell LymphomaActive, not recruitingNCT05951959Phase 2
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaActive, not recruitingNCT05948475Phase 3
• Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
• A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeActive, not recruitingNCT05946941Phase 3
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue SarcomaSuspendedNCT05941325Phase 2
• Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaCompletedNCT05940064Phase 2
• Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related PolyneuropathyActive, not recruitingNCT05939037Phase 2
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)CompletedNCT05934526Phase 3
• HMPL-453 Food Effect and PPI Study in Healthy Volunteer StudyCompletedNCT05930119Phase 1
• First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKIActive, not recruitingNCT05920135Phase 1/2
• A Phase 1 Study of BMF-500 in Adults With Acute LeukemiaCompletedNCT05918692Phase 1
• A Food Effect Study of LP-168 Tablets in Healthy SubjectsCompletedNCT05917964Phase 1
• Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic CholangiocarcinomaStatus unknownNCT05913661Phase 2
• Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum DisordersWithdrawnNCT05909943Phase 1/2
• Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic CancerCompletedNCT05908747Phase 2
• Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsCompletedNCT05904730Phase 1
• Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular CarcinomaActive, not recruitingNCT05901194Phase 1/2
• The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor PneumoniaCompletedNCT05899725Not applicable
• A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult ParticipantsCompletedNCT05896683Phase 1
• A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the BrainActive, not recruitingNCT05892068Phase 2
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyActive, not recruitingNCT05889182Phase 3
• A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male SubjectsCompletedNCT05888207Phase 1
• A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGLStatus unknownNCT05883085Phase 2
• A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05880706Phase 2
• Ritlecitinib in CTCLTerminatedNCT05879458Phase 2
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCCCompletedNCT05877820Phase 2
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersActive, not recruitingNCT05873686Phase 1
• [14 C] Study on Mass Balance of TY-9591 in Healthy Chinese SubjectsCompletedNCT05871905Phase 1
• Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell LymphomaActive, not recruitingNCT05864742Phase 2
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingNCT05859334Phase 2
• REVERSE-Long COVID-19 With Baricitinib StudyWithdrawnNCT05858515Phase 3
• A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusCompletedNCT05856448Phase 2
• To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative BioavailabilityCompletedNCT05856058Phase 1
• Baricitinib in Idiopathic Granulomatous MastitisActive, not recruitingNCT05852171Phase 2
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaActive, not recruitingNCT05851443Phase 2
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2
• A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)CompletedNCT05844956Phase 1/2
• Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusActive, not recruitingNCT05843643Phase 3
• Dasatinib Plus Quercetin for Accelerated Aging in Mental DisordersActive, not recruitingNCT05838560Phase 2
• A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in HumanStatus unknownNCT05836805Phase 1
• Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaActive, not recruitingNCT05836571Phase 2
• Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05831891Phase 2
• Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing SarcomaActive, not recruitingNCT05830084Phase 1
• Anlotinib Capsules in the Treatment for IPF/PF-ILDsActive, not recruitingNCT05828953Phase 2
• A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWithdrawnNCT05828303Phase 1
• A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsWithdrawnNCT05828277Phase 1
• Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical TrialStatus unknownNCT05827497Phase 4
• Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance StatusStatus unknownNCT05826483Phase 1
• DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT05824585Phase 1
• Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial CancerActive, not recruitingNCT05824481Phase 2
• Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerActive, not recruitingNCT05824468Phase 2
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• Deucravacitinib in PGWithdrawnNCT05821374Early Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid TumorsStatus unknownNCT05818917Phase 1
• A Phase Ia Safety and Tolerability Study of BL-001CompletedNCT05818306Phase 1
• A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy SubjectsCompletedNCT05817240Phase 1
• Pilot Study of Imatinib Cetuximab Combo for H & N CancerCompletedNCT05816785Early Phase 1
• Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05816499Phase 1/2
• Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian CancerCompletedNCT05815862Phase 2
• Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyTerminatedNCT05815160Phase 1
• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT05814627Phase 3
• Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT05801107Phase 2
• A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsActive, not recruitingNCT05801029Phase 2
• Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingNCT05798507Early Phase 1
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric CancerActive, not recruitingNCT05795296Phase 2
• Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT05792462Phase 1
• A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingNCT05787561Phase 2
• Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior LazertinibCompletedNCT05786430Phase 2
• A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisActive, not recruitingNCT05785611Phase 3
• Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.Status unknownNCT05785208Phase 4
• Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.Active, not recruitingNCT05782907Phase 3
• POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1
• Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese SubjectsCompletedNCT05781906Phase 1
• Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral TreatmentCompletedNCT05780073Phase 2
• Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2
• A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCCCompletedNCT05773105Phase 1/2
• Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)TerminatedNCT05770882Phase 1/2
• A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male SubjectsCompletedNCT05768360Phase 1
• Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFRStatus unknownNCT05767866Phase 1/2
• Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult ParticipantsCompletedNCT05767398Phase 1
• Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRTStatus unknownNCT05763927Phase 2
• Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerActive, not recruitingNCT05759572Phase 2
• A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy ParticipantsCompletedNCT05753592Phase 1
• Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid CancerCompletedNCT05745363Phase 1/2
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingNCT05743244Phase 2
• ZN-c3 in Adult Participants With Metastatic Colorectal CancerTerminatedNCT05743036Phase 1
• A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract CancerCompletedNCT05742750Phase 1/2
• A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult ParticipantsCompletedNCT05742594Phase 1

← Tyrosine Kinase Inhibitors overview